Medicine and Dentistry
Hidradenitis Suppurativa
100%
Cohort Analysis
50%
Biological Product
26%
Retinoid
25%
Cystic Fibrosis
25%
Infliximab
25%
Adalimumab
25%
Surgical Risk
25%
Guselkumab
25%
Risk Stratification
25%
Drug Interaction
25%
Endometrial Cancer
25%
Action Study
25%
Disease
16%
Clinical Trial
16%
Survival Time
16%
Etretin
14%
Nonsteroid Antiinflammatory Agent
12%
Disease Duration
12%
Etiology
12%
Papule
12%
Isotretinoin
10%
Kaplan Meier Method
9%
Proportional Hazards Model
9%
Survival Rate
9%
Disease Severity
8%
Dermatosis
8%
Scar Formation
7%
Folliculitis
7%
Comedo
7%
Treatment Duration
7%
Necrosis
6%
Side Effect
6%
Dermatology
6%
Survival Prediction
6%
Placebo
5%
Keyphrases
Hidradenitis Suppurativa
75%
Physical Activity
26%
Guselkumab
26%
Dutch Cohort
25%
Low-risk Endometrial Cancer
25%
Comorbidity
25%
Impacts of Environmental Factors
25%
Tool Classification
25%
Population-based
25%
Smoking Behavior
25%
New Treatment Options
25%
Socioeconomic Status
25%
Aquagenic Wrinkling of the Palms
25%
Risk Reduction
25%
Northern Netherlands
10%
Infectiveness
8%
Mental Health
6%
Comedones
6%
Fibromyalgia
6%
Mediterranean Diet Score
5%
Dutch Dietary Guidelines
5%
Lifelines Diet Score
5%
Preoperative Risk Stratification
5%
Pharmacology, Toxicology and Pharmaceutical Science
Suppurative Hidradenitis
100%
Cohort Study
52%
Biological Product
26%
Infliximab
25%
Comorbidity
25%
Adalimumab
25%
Guselkumab
25%
Prevalence
25%
Retinoid
25%
Survival Rate
19%
Survival Time
16%
Etretin
14%
Disease Duration
12%
Isotretinoin
10%
Comedo
7%
Folliculitis
7%
Scar Formation
7%
Side Effect
6%
Necrosis
6%
Survival Prediction
6%
Placebo
5%